Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 15 (5) , 929-941
Abstract
The mTORC1 inhibitors, such as rapamycin and its analogs, show limited antitumor activity in clinic, reasons for which have not been clearly elucidated. Here, we undertook an effort to uncover the mechanisms underlying the limited efficacy of rapamycin, and found that the transit suppression of 4EBP1 phosphorylation led to cap-dependent translation and cell proliferation in breast cancer cells. AKT only partially contributed to 4EBP1 re-phosphorylation. By taking advantage of mass spectrometry-based phosphoproteomic analysis, we identified SGK3 as a potent kinase involved in 4EBP1 re-phosphorylation. SGK3 deletion inhibited 4EBP1 phosphorylation and cap-dependent translation. Importantly, 4EBP1 phosphorylation was positively correlated with SGK3 activity in 67 clinical breast cancer specimens. Moreover, SGK3 deletion in combination with AKT inhibition almost blocked the 4EBP1 re-phosphorylation that was induced by rapamycin and profoundly enhanced rapamycin-induced growth inhibition in vitro and in an MCF7 breast cancer mouse xenograft model in vivo. Mechanistically, the feedback activation of SGK3 by rapamycin was dependent on hVps34 and mTORC2, and reactivated mTORC1/4EBP1 axis by phosphorylating TSC2. Collectively, our study reveals a critical role of SGK3 in mediating rapamycin resistance, and provides a rationale for targeting SGK3 to improve mTOR-targeted therapies.Keywords
This publication has 37 references indexed in Scilit:
- AKT-independent PI3-K signaling in cancer – emerging role for SGK3Cancer Management and Research, 2013
- Rapalogs and mTOR inhibitors as anti-aging therapeuticsJournal of Clinical Investigation, 2013
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO StudyJournal of Clinical Oncology, 2012
- SGK3 is associated with estrogen receptor expression in breast cancerBreast Cancer Research and Treatment, 2012
- SGK3 Is an Estrogen-Inducible Kinase Promoting Estrogen-Mediated Survival of Breast Cancer CellsMolecular Endocrinology, 2011
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human CancerCancer Cell, 2009
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translationProceedings of the National Academy of Sciences, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanismOncogene, 2006
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006